In vitro efficacy of diclofenac against Listeria monocytogenes

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
N K DuttaJae-Hak Park

Abstract

Chemotherapy is often futile in systemic listeriosis, translating to being a peril to public health. There is, thus, an imperative need for novel antilisterial compounds, possibly acting through mechanisms dissimilar to those of existing drugs. The present study describes one such agent-the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium (Dc). The National Committee for Clinical Laboratory Standards (NCCLS) minimum inhibitory concentration (MIC), mode of action, and two mechanisms of action, i.e., on bacterial DNA and membrane, have been characterized with respect to Dc. The drug showed noteworthy inhibitory action (MIC90 = 50 microg/ml) against Listeria strains, demonstrated cidal (minimum bactericidal concentration [MBC]=100 microg/ml) activity, inhibited listerial DNA synthesis (45.48%; incorporation of [methyl-3H] thymidine), and possessed bacterial membrane-damaging activity (37.33%; BacLight assay). Dc could be used as a lead compound for the synthesis of new, more active agents perhaps devoid of side effects. Further, quantitative structure-activity relationship (QSAR) studies will contribute to a new generation of promising adjuvants to existing antilisterial drugs.

References

Sep 1, 1995·Antimicrobial Agents and Chemotherapy·J M WilsonI Chopra
May 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S Muñoz-CriadoJ A García-Rodríguez
Nov 1, 2006·Emerging Infectious Diseases·Iain A GillespieMartyn Regan
Jul 24, 2007·International Journal of Antimicrobial Agents·Noton Kumar DuttaLeonard Amaral
Jul 24, 2007·International Journal of Antimicrobial Agents·Noton Kumar DuttaJae-Hak Park
Aug 28, 2007·Microbes and Infection·Bala Swaminathan, Peter Gerner-Smidt

❮ Previous
Next ❯

Citations

Dec 25, 2013·Hernia : the Journal of Hernias and Abdominal Wall Surgery·A ReślińskiK Głowacka
Feb 3, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N K DuttaS G Dastidar
Apr 29, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K MazumdarN K Dutta
Jan 25, 2014·Science·Miyoshi HarutaMichael R Sussman
Apr 1, 2014·Bioinformatics·Sung Kyu Robin ParkJohn R Yates
Feb 4, 2012·Science·Jeffrey N SavasMartin W Hetzer
Aug 27, 2015·Journal of Pharmaceutical Sciences·Joshua Boateng, Ovidio Catanzano
Jul 23, 2008·Letters in Applied Microbiology·N K DuttaJ H Park
Jul 27, 2010·Applied and Environmental Microbiology·Henk C den BakkerMartin Wiedmann
Oct 16, 2016·Cold Spring Harbor Perspectives in Medicine·Susanne Paukner, Rosemarie Riedl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.